We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Momenta (MNTA) Q1 Loss Narrower than Expected, Sales Beat
Read MoreHide Full Article
Momenta Pharmaceuticals Inc. reported loss of 46 cents per share in the first quarter of 2017,which was narrower than the Zacks Consensus Estimate loss of $1.09. In fact, the company posted a loss of 35 cents in the year-ago quarter as well.
But revenues in the quarter surged 34.1% to $26.6 million and topped the Zacks Consensus Estimate of $22 million.
Shares of Momenta have underperformed the Zacks categorized Medical-Biomedical and Genetics industry in year to date. The stock rallied 4.6% compared with the industry’s gain of 5.4%.
Quarter in Detail
Momenta’s top line comprises product revenues of $23.4 million earned from Sandoz’s sales of Glatopa, a generic version of Copaxone (20 mg), compared with $14.8 million in the year-ago quarter. The increase was on the back of increased number of Glatopa 20 mg units sold.
Collaborative research and development revenues came in at $3.2 million, down from $5.1 million in the year-ago quarter. The decline in revenues was mainly due to the termination of the Baxalta Collaboration Agreement, effective Dec 31, 2016.
While, research and development expenses were up 25.5% to $36.1 million, general and administrative expenses increased 47.7% to $23.1 million.
Outlook
Momenta reiterated its guidance for operating expenses for 2017. The company expects operating expenses (excluding stock-based compensation and net of collaborative revenues) in the range of $200–$240 million in 2017. The guidance also includes approximately $55 million of capital expenditure on M923 slated for 2017. Operating expenses in the second quarter of 2017 are projected around $50–$60 million.
Collaboration revenues, under its agreement with Mylan are anticipated to be $1.8 million per quarter. Moreover, the company anticipates to recognize the $50 million upfront payment from CSL as revenues in the second half of 2017.
Pipeline Update
Sandoz’s abbreviated New Drug Application (ANDA) for the 40-mg thrice-weekly formulation of Copaxone (Glatopa 40mg) was under the FDA review. However, Momenta suffered a setback with the FDA issuing a warning letter to Pfizer (PFE - Free Report) , which is Sandoz’s contracted fill/finish manufacturing partner for Glatopa.
In fact, the ANDA approval is now contingent on the satisfactory resolution of the compliance observations stated in the warning letter issued to Pfizer. Pfizer submitted a comprehensive response to the observations cited in the warning letterMeanwhile, Momenta continues to progress with its other pipeline candidates. In fact, under its collaboration with Mylan in Apr 2017, the company completed enrolment in the phase I study on M834, a biosimilar version of Orencia (abatacept). Top-line data from the study are expected in the second half of 2017.
Again, in Dec 2016, the company inked an early termination of the collaboration agreement with Shire plc , to develop and commercialize M923, a biosimilar version of Humira (adalimumab). In lieu, the company received a one-time asset return payment of $51.2 million from Shire in Jan 2017.
Currently, Momenta’s M923 is being evaluated in a phase III study. It announced positive results from a phase III study on M923 in patients suffering from moderate-to-severe chronic plaque psoriasis. Moving ahead, the company plans to submit the candidate for approval to regulatory bodies by mid-2017. Also, it expects first commercial launch of M923 to be as early as the 2020 timeframe.
Furthermore, Momenta’s novel autoimmune portfolio includes two recombinant molecules: M230, a Selective Immunomodulator of Fc receptors (SIF3) and M281, an anti-FcRn monoclonal antibody. In Jan 2017, the company entered into a research collaboration and license agreement with CSL for M230 and potential future Fc multimer programs. The candidate is expected to enter clinic in 2017.
In fact, this company successfully completed a phase I single ascending dose study in healthy volunteers for M281. The multiple ascending dose portion of the study was initiated in Jan 2017 and data from the single and multiple ascending dose portions of the study are projected in the second half of 2017.
M254 is a tetra-Fc-sialylated immunoglobulin with consistent enhanced anti-inflammatory activity. The company continues to progress the M254 program and expects to initiate an investigational new drug (IND)-enabling toxicology study in 2017 and is anticipated to enter a clinical study in 2018.
Our Take
The company posted narrower-than-expected loss and sales beat estimates in the first quarter of 2017. The ANDA approval for Glatopa is contingent on the satisfactory resolution of the compliance observations stated in the warning letter issued by the FDA, resulting in a delay of approval. Notably, the warning letter will remain a drag on the company's shares till the issue is solved.
However, sales of Glatopa 20mg continue to do well. In addition, a potential submission of M923 for approval in mid-2017 will boost investor confidence. Further, Momenta may collaborate with some other company for the future development and commercialization of the drug.
Momenta Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research. It's not the one you think. See This Ticker Free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Momenta (MNTA) Q1 Loss Narrower than Expected, Sales Beat
Momenta Pharmaceuticals Inc. reported loss of 46 cents per share in the first quarter of 2017,which was narrower than the Zacks Consensus Estimate loss of $1.09. In fact, the company posted a loss of 35 cents in the year-ago quarter as well.
But revenues in the quarter surged 34.1% to $26.6 million and topped the Zacks Consensus Estimate of $22 million.
Shares of Momenta have underperformed the Zacks categorized Medical-Biomedical and Genetics industry in year to date. The stock rallied 4.6% compared with the industry’s gain of 5.4%.
Quarter in Detail
Momenta’s top line comprises product revenues of $23.4 million earned from Sandoz’s sales of Glatopa, a generic version of Copaxone (20 mg), compared with $14.8 million in the year-ago quarter. The increase was on the back of increased number of Glatopa 20 mg units sold.
Collaborative research and development revenues came in at $3.2 million, down from $5.1 million in the year-ago quarter. The decline in revenues was mainly due to the termination of the Baxalta Collaboration Agreement, effective Dec 31, 2016.
While, research and development expenses were up 25.5% to $36.1 million, general and administrative expenses increased 47.7% to $23.1 million.
Outlook
Momenta reiterated its guidance for operating expenses for 2017. The company expects operating expenses (excluding stock-based compensation and net of collaborative revenues) in the range of $200–$240 million in 2017. The guidance also includes approximately $55 million of capital expenditure on M923 slated for 2017. Operating expenses in the second quarter of 2017 are projected around $50–$60 million.
Collaboration revenues, under its agreement with Mylan are anticipated to be $1.8 million per quarter. Moreover, the company anticipates to recognize the $50 million upfront payment from CSL as revenues in the second half of 2017.
Pipeline Update
Sandoz’s abbreviated New Drug Application (ANDA) for the 40-mg thrice-weekly formulation of Copaxone (Glatopa 40mg) was under the FDA review. However, Momenta suffered a setback with the FDA issuing a warning letter to Pfizer (PFE - Free Report) , which is Sandoz’s contracted fill/finish manufacturing partner for Glatopa.
In fact, the ANDA approval is now contingent on the satisfactory resolution of the compliance observations stated in the warning letter issued to Pfizer. Pfizer submitted a comprehensive response to the observations cited in the warning letterMeanwhile, Momenta continues to progress with its other pipeline candidates. In fact, under its collaboration with Mylan in Apr 2017, the company completed enrolment in the phase I study on M834, a biosimilar version of Orencia (abatacept). Top-line data from the study are expected in the second half of 2017.
Again, in Dec 2016, the company inked an early termination of the collaboration agreement with Shire plc , to develop and commercialize M923, a biosimilar version of Humira (adalimumab). In lieu, the company received a one-time asset return payment of $51.2 million from Shire in Jan 2017.
Currently, Momenta’s M923 is being evaluated in a phase III study. It announced positive results from a phase III study on M923 in patients suffering from moderate-to-severe chronic plaque psoriasis. Moving ahead, the company plans to submit the candidate for approval to regulatory bodies by mid-2017. Also, it expects first commercial launch of M923 to be as early as the 2020 timeframe.
Furthermore, Momenta’s novel autoimmune portfolio includes two recombinant molecules: M230, a Selective Immunomodulator of Fc receptors (SIF3) and M281, an anti-FcRn monoclonal antibody. In Jan 2017, the company entered into a research collaboration and license agreement with CSL for M230 and potential future Fc multimer programs. The candidate is expected to enter clinic in 2017.
In fact, this company successfully completed a phase I single ascending dose study in healthy volunteers for M281. The multiple ascending dose portion of the study was initiated in Jan 2017 and data from the single and multiple ascending dose portions of the study are projected in the second half of 2017.
M254 is a tetra-Fc-sialylated immunoglobulin with consistent enhanced anti-inflammatory activity. The company continues to progress the M254 program and expects to initiate an investigational new drug (IND)-enabling toxicology study in 2017 and is anticipated to enter a clinical study in 2018.
Our Take
The company posted narrower-than-expected loss and sales beat estimates in the first quarter of 2017. The ANDA approval for Glatopa is contingent on the satisfactory resolution of the compliance observations stated in the warning letter issued by the FDA, resulting in a delay of approval. Notably, the warning letter will remain a drag on the company's shares till the issue is solved.
However, sales of Glatopa 20mg continue to do well. In addition, a potential submission of M923 for approval in mid-2017 will boost investor confidence. Further, Momenta may collaborate with some other company for the future development and commercialization of the drug.
Momenta Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Momenta Pharmaceuticals, Inc. Price, Consensus and EPS Surprise | Momenta Pharmaceuticals, Inc. Quote
Zacks Rank
Momenta currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research. It's not the one you think. See This Ticker Free >>